Records containing: Multiple Myeloma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-02-14A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207)
-
CLINICAL_TRIALS study record update · 2025-02-11Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients- a Randomized, Placebo Controlled Phase II Trial "DEFENCE" (DEnosumab For the rEductioN of the Smoldering Myeloma transformatioN inCidence ratE)
-
CLINICAL_TRIALS study record update · 2025-02-10Telehealth-based Symptom Management for Veterans Treated With Selinexor
-
CLINICAL_TRIALS study record update · 2025-02-05Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine
-
CLINICAL_TRIALS study record update · 2025-02-04ClinicalTrials.gov study NCT05238311
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-02-03A Prospective, Single-Arm, Multicenter, Pragmatic Phase-IV Trial Investigating Safety and Effectiveness of DARZALEX (Daratumumab) In Indian Subjects With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
-
CLINICAL_TRIALS study record update · 2025-02-03Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-02-03A Phase 1b Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone (DRd) in Japanese Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
-
CLINICAL_TRIALS study record update · 2025-02-03Multiple Myeloma Patient Registry
-
CLINICAL_TRIALS study record update · 2025-01-31An Observational Trial Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-01-30A Randomized Phase II Trial Comparing Bendamustine and Melphalan With Melphalan Alone as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Myeloma Patients
-
CLINICAL_TRIALS study record update · 2025-01-27A Phase 1 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of LAVA-051 in Patients with Relapsed or Refractory CLL, MM, or AML
-
CLINICAL_TRIALS study record update · 2025-01-22Proteomic Analysis of Patients Undergoing Bariatric Surgery
-
CLINICAL_TRIALS study record update · 2025-01-20A Phase 1 Study of Autologous Memory-like Natural Killer (NK) Cell Immunotherapy With BHV-1100 and IVIG Followed by Low Dose IL-2 as Early Post-Autologous Transplant Consolidation in Minimal Residual Disease Positive, Multiple Myeloma (MM) Patients in First or Second Remission
-
CLINICAL_TRIALS study record update · 2025-01-16A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-01-16Immune Profiling in Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-01-15Carfilzomib - Lenalidmide - Dexamethasone (KRd) Versus Lenalidomi - Dexamethasone (Rd) in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation: a Randomized Phas III Trial
-
CLINICAL_TRIALS study record update · 2025-01-15Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing After or Refractory to Anti-BCMA CAR-T Therapies
-
CLINICAL_TRIALS study record update · 2025-01-15Observational Study in Patient With Multiple Myeloma Relapse/Refractory Treated With Belantamab Mafotidine on Monotherapy Previously Exposed to at Least One Proteasome Inhibitor, Immunomodulatory Agent, and Anti-CD38 Antibody.
-
CLINICAL_TRIALS study record update · 2025-01-14Normal Range Study for Free Light Chains in Blood Among Identical or Fraternal Twins
-
CLINICAL_TRIALS study record update · 2025-01-09IBEX: Phase 2 Trial of Iberdomide + SQ Daratumumab As Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-01-08A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects With Relapsed or Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-01-08A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-01-07A Clinical Trial to Explore the Safety and Efficacy of CT071 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia
-
CLINICAL_TRIALS study record update · 2025-01-06Efficacy and Safety Study of Anti-BCMA/FcRL5 CAR-T Cells in Subjects With Relapsed and Refractory Multiple Myeloma